Product Description
Antithrombin III is a protein in the blood that blocks abnormal blood clots from forming. It helps the body keep a healthy balance between bleeding and clotting. Congenital antithrombin III deficiency is an inherited disease. It occurs when a person receives one abnormal copy of the antithrombin III gene from a parent with the disease. (Sourced from: https://medlineplus.gov/ency/article/000558.htm)
Mechanisms of Action: SP Inhibitor, Thrombin Inhibitor
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Belgium | Brazil | Bulgaria | Canada | Chile | Colombia | Croatia | Czech | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Indonesia | Ireland | Italy | Japan | Korea | Latvia | Lithuania | Luxembourg | Malta | Mexico | Netherlands | New Zealand | Norway | Poland | Portugal | Romania | Russia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Turkey | Ukraine | United Kingdom | United States
Approved Indications: None
Known Adverse Events: None
Company: Grifols
Company Location: Eastern America
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China, Japan
Active Clinical Trial Count: 2
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Antithrombin III Deficiency|Venous Thrombosis
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
CTR20232591 |
CTR20232591 | P3 |
Completed |
Venous Thrombosis|Antithrombin III Deficiency |
2025-06-05 |
2025-11-02 |
Patient Enrollment|Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
jRCT2031230269 |
jRCT2031230269 | P3 |
Recruiting |
Unknown |
1970-01-01 |